New Genomic Test Could Spare some People with Melanoma From Lymph Node Biopsy Surgery

New genomic test could spare some people with melanoma from lymph node biopsy surgery

A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes—a finding that could guide treatment decisions and help many people avoid lymph node biopsy surgery. The study results are published in JAMA Surgery.

New Genomic Test May Help Melanoma Patients Avoid Lymph Node Biopsy Surgery

In a groundbreaking advancement within oncology, researchers at Mayo Clinic, in collaboration with SkylineDx, have unveiled a novel genomic test that promises to revolutionize the management of melanoma by predicting the likelihood of cancer’s presence in the lymph nodes. Published in the prestigious journal JAMA Surgery, this test harnesses cutting-edge molecular diagnostics to guide therapeutic […]